MPM BioImpact LLC - BLACK DIAMOND THERAPEUTICS I ownership

BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 73 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q3 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.

Quarter-by-quarter ownership
MPM BioImpact LLC ownership history of BLACK DIAMOND THERAPEUTICS I
ValueSharesWeighting
Q1 2023$273,838
+5.0%
144,8880.0%0.07%
+4.4%
Q4 2022$260,798
-35.6%
144,888
-39.6%
0.07%
-29.2%
Q3 2022$405,000
-31.4%
239,8880.0%0.10%
-41.5%
Q2 2022$590,000
-11.1%
239,8880.0%0.16%
-7.9%
Q1 2022$664,000
-48.1%
239,8880.0%0.18%
-23.6%
Q4 2021$1,279,000
-39.2%
239,888
-3.5%
0.23%
-28.5%
Q3 2021$2,102,000
+50.4%
248,506
+469.8%
0.33%
+169.4%
Q4 2020$1,398,00043,6150.12%
Other shareholders
BLACK DIAMOND THERAPEUTICS I shareholders Q3 2023
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 634,191$1,820,1282.14%
NEA Management Company, LLC 4,448,757$12,767,9330.99%
CHI Advisors LLC 720,000$2,066,4000.82%
Bellevue Group AG 8,135,839$23,349,8580.38%
Parkman Healthcare Partners LLC 520,587$1,494,0850.27%
Artal Group S.A. 2,046,517$5,8740.25%
RA Capital Management 3,525,754$10,118,9140.20%
Ikarian Capital, LLC 555,572$1,594,4920.19%
TANG CAPITAL MANAGEMENT LLC 400,000$1,148,0000.16%
Newtyn Management, LLC 205,000$588,3500.14%
View complete list of BLACK DIAMOND THERAPEUTICS I shareholders